Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
5 Stocks to Bet on in an Innovation-Driven Drug Industry
02:31pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.
5 Stocks to Bet on in an Innovation-Driven Drug Industry
12:02pm, Thursday, 20'th Oct 2022
Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.
Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?
01:40pm, Wednesday, 19'th Oct 2022 Zacks Investment Research
Here is how Catalyst Pharmaceutical (CPRX) and AxoGen (AXGN) have performed compared to their sector so far this year.
Reata (RETA) Up After FDA Scraps AdCom Meeting for NDA Filing
04:52pm, Monday, 17'th Oct 2022 Zacks Investment Research
The FDA decides not to hold an advisory committee meeting for Reata Pharmaceuticals' (RETA) regulatory filing seeking approval for omaveloxolone in Friedreich's Ataxia.
Moderna (MRNA) Up After Merck Exercises Option for Cancer Jab
03:27pm, Thursday, 13'th Oct 2022 Zacks Investment Research
Merck (MRK) exercises an option to jointly develop and commercialize Moderna's (MRNA) personalized cancer vaccine as part of an existing collaboration agreement between the companies.
United Therapeutics (UTHR) Initiates Tyvaso Study in IPF
04:14pm, Wednesday, 12'th Oct 2022 Zacks Investment Research
United Therapeutics (UTHR) initiates a second phase III study evaluating its Tyvaso inhalation solution. The study will be conducted in sites outside the United States and Canada.
Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why
03:23pm, Monday, 10'th Oct 2022 Zacks Investment Research
Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.
Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why
12:47pm, Monday, 10'th Oct 2022
Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
03:01am, Tuesday, 04'th Oct 2022
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.
Is Catalyst Pharmaceuticals (CPRX) Stock Outpacing Its Medical Peers This Year?
01:40pm, Monday, 03'rd Oct 2022 Zacks Investment Research
Here is how Catalyst Pharmaceutical (CPRX) and IMARA Inc. (IMRA) have performed compared to their sector so far this year.
Is Catalyst Pharmaceuticals (CPRX) Stock Outpacing Its Medical Peers This Year?
11:17am, Monday, 03'rd Oct 2022
Here is how Catalyst Pharmaceutical (CPRX) and IMARA Inc. (IMRA) have performed compared to their sector so far this year.
Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA
03:47pm, Friday, 30'th Sep 2022 Zacks Investment Research
Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.
Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA
12:48pm, Friday, 30'th Sep 2022
Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.
Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients
03:18pm, Thursday, 29'th Sep 2022 GlobeNewswire Inc.
FIRDAPSE is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S. FIRDAPSE is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S.
2 No-Brainer Stocks to Buy Right Now for Less Than $15
02:30pm, Wednesday, 28'th Sep 2022 The Motley Fool
Their low price tags belie their massive long-term potential.
